^
    Apply
    Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies (NCT04641871)
    Phase 1
    Symphogen A/S
    Active, not recruiting
    Last update posted :
    04/24/2024
    Initiation :
    10/12/2020
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    FGFR2 • IDH1
    |
    IDH1 mutation • FGFR2 mutation • FGFR2 fusion
    |
    irinotecan • S95018 • Sym021 • Sym022